Nevi And Melanomas
Mostrando 1-12 de 13 artigos, teses e dissertações.
-
1. Hereditary melanoma: a five-year study of Brazilian patients in a cancer referral center - phenotypic characteristics of probands and pathological features of primary tumors
Abstract: BACKGROUND: Approximately five to 10% of all melanomas occur in families with hereditary predisposition and the main high-risk melanoma susceptibility gene is the CDKN2A. OBJECTIVES: To describe, after a five-years study, the clinical data of patients (probands) from familial melanoma kindreds, and the pathological characteristics of their melano
An. Bras. Dermatol.. Publicado em: 2018-06
-
2. A prospective study of patients with large congenital melanocytic nevi and the risk of melanoma
Abstract: Background: Large congenital melanocytic nevus (LCMN) is considered a risk factor for melanoma, although the magnitude of this risk is controversial. Objective: To evaluate the risk of melanoma development in patients with LCMN seen at a dermatology referral center in Brazil during a twelve-year period. To the best of our knowledge, there are no
An. Bras. Dermatol.. Publicado em: 2017-03
-
3. Melanoma associated with congenital intermediate common blue nevus of the scalp - Case report
Abstract: Melanomas can arise either de novo (70%) or from pre-existing melanocytic lesions (30%). Of the latter, most cases arise at the dermoepidermal junction from small congenital or acquired non-blue nevi while only a few arise from blue nevi, notably the cellular subtype and less commonly the common (dendritic) type. Melanomas that arise from blue nevi
An. Bras. Dermatol.. Publicado em: 2016-08
-
4. Obtaining molecular markers for prognostic and diagnosis of cutaneous malignant melanoma. / Obtenção de marcadores moleculares para prognóstico e diagnóstico de melanoma cutâneo maligno.
The incidence of malignant skin melanoma (MM) increases around 2,5 a 4% each year in the world. The main risk factors are family history of MM, multiple benign or atypical nevi, and additional factors such as immunossuppression, sun sensibility and UV exposure. Genomic instability is responsible for a collection of mutations that are frequently involved in m
Publicado em: 2009
-
5. Expressão de proteínas da apoptose em melanoma cutâneo primário / Apoptosis proteins expression in cutaneous melanoma
Cutaneous melanoma still constitutes the main cause of skin cancer death in developed world. Clinical behavior variability of this neoplasia has been only partially explained by clinical and histological aspects, and identification of biological variables can be important for determining specific risk groups. Sixty nine (69) patients with mild to severe prim
Publicado em: 2009
-
6. Efeitos da radiação ultravioleta b na expressão imunoistoquímica das metaloproteinases –2 e –9 em nevos melanocíticos / Acute effects of ultraviolet radiation B in immunohistochemical expression of matrix metalloproteinases –2 and –9 in melanocytic nevi
Introdução: a incidência dos melanomas permanece em ascensão em diversos países. Os nevos melanocíticos podem ser seus precursores ou marcadores de risco. A radiação ultravioleta é o principal fator de risco ambiental para o seu desenvolvimento. Estudos com nevos irradiados mostram que a radiação ultravioleta B (UVB) pode causar alterações morfo
Publicado em: 2007
-
7. The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes
Melanocytic nevi frequently harbor oncogenic BRAF mutations, but only a minority progress to melanoma. In human melanocytes, persistent BRAFV600E expression triggers oncogene-induced senescence, which implies that bypass of oncogene-induced senescence is necessary for malignant transformation of melanocytes. We show that a subpopulation of primary human mela
American Society for Investigative Pathology.
-
8. Malignant Melanoma—Profile of an Epidemic
Cutaneous malignant melanoma is occurring in epidemic proportions in the United States. To provide a profile of persons at risk and the epidemiologic features of malignant melanoma, we reviewed the records of 325 patients with cutaneous malignant melanoma seen at the University of Colorado Health Sciences Center between 1973 and 1983. Most patients had fair
-
9. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily.
The MUC18 antigen is an integral membrane glycoprotein of 113 kDa whose expression on primary human melanomas correlates with poor prognosis and the development of metastatic disease. MUC18 is expressed only sporadically in benign melanocytic nevi and thin primary melanomas that have a low probability of metastasizing. However, with increasing tumor thicknes
-
10. Transgenic mouse model of malignant skin melanoma.
Tyr-SV40E transgenic mice are specifically susceptible to melanoma due to expression of the oncogene in pigment cells. Mice of the more susceptible lines die young of early-onset eye melanomas, when skin melanomas are still infrequent and benign. To surmount this obstacle, skin from donors of two high-susceptibility lines was grafted to Tyr-SV40E hosts of a
-
11. Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies.
The nerve growth factor (NGF) receptor was characterized by using a new series of anti-receptor monoclonal antibodies (MAbs). These MAbs (i) showed significantly greater reactivity with a melanoma cell line expressing higher levels of NGF receptor, (ii) inhibited the binding of 125I-labeled NGF to its receptor, and (iii) immunoprecipitated both metabolically
-
12. Polymorphisms of the BRAF gene predispose males to malignant melanoma
The incidence of malignant melanoma has rapidly increased in recent years. Evidence points to the role of inheritance in melanoma development, but specific genetic risk factors are not well understood. Recent reports indicate a high prevalence of somatic mutations of the BRAF gene in melanomas and melanocytic nevi. Here we report that germ-line single nucleo
BioMed Central.